



EUROPEAN COMMISSION

HEALTH & CONSUMERS DIRECTORATE-GENERAL

Brussels,  
SANCO G (2011) 754865

**STANDING COMMITTEE ON THE FOOD CHAIN AND ANIMAL HEALTH**

Section *PLANT PROTECTION PRODUCTS – LEGISLATION*

**16-17 June 2011**

President: Michael Flüh

*All Member States were present.*

*Qualified majority: 255 votes and 14 Member States in favour.*

**SECTION A Information and/or discussion**

**1. Exchange of views and possible taking note on a draft Guidance Document SANCO/10597/2003 on the assessment of the equivalence of technical materials.**

The Committee took note of the Guidance Document SANCO/10597/2003.

**2. Oxamyl – confirmatory data – revised review report (Doc. SANCO/10212/05 final Rev. 1)**

The Committee took note of the review report outlined in document SANCO/10212/05 final Rev. 1.

**3. Myclobutanil –revised review report (Doc. SANCO/1339/2010 final Rev. 1).**

The Committee took note of the review report outlined in document SANCO/1339/2010 final Rev. 1.

**4. Cyromazine – revised review report (Doc. SANCO/4459/09 final Rev. 1).**

The Committee took note of the review report outlined in document SANCO/4459/09 final Rev. 1.

**5. Notifications under Article 8(4) of the Directive.**

Chloridazon/Quinmerac (BE)

n-Decanol (BE)

1, 3-Dichloropropene (BE)

Abamectin (BG)

Imidacloprid/Pencycuron (BG)  
Tau-fluvalinate (BG)  
Tebuconazole (BG)  
Oxamyl (CZ)  
Spiroxamine (CZ)  
Gibberellic acid (DE)  
Cypermethrin (ES)  
Dichlorvos (ES)  
Emamectine (ES)  
Aclonifen (HU)  
Penoxsulam (HU)  
Phenmedipham/Desmedipham (HU)  
Deltamethrin (IE)  
Linuron (IE)  
Acetamipride (PL)  
Ammonium acetate+Triethylaminehydrochloride+Putresine (PT)  
Clomazone/Metribuzin (PT)  
Metaflumizone (PT)  
Propanil (PT)  
Pyriproxyfen (PT)  
Tricyclazole (PT)  
Pheroprax (SE)  
Betanal (SE)  
Fenoxycarb (SK)

The Committee took note of the notifications submitted by Belgium, Bulgaria, Czech Republic, Germany, Spain, Hungary, Ireland, Poland, Portugal, Sweden and Slovakia.

The Commission recalls that under the provisions of article 8(4) Member States are obliged to inform the Commission and the other Member States immediately after they have granted such derogation.

In addition, the Commission pointed out that if a Maximum Residue Level (MRL) set under Reg. (EC) No 396/2005 cannot be met and a national MRL is set, nevertheless, a consumer risk assessment has to be carried out and forwarded to the Commission, the European Food Safety Authority and Member States.

Member States are reminded that they shall put in place the necessary risk mitigation measures to ensure acceptable uses for human and animal health and the environment.

## **SECTION B Drafts presented for an opinion**

- 1. Exchange of views and possible opinion of the Committee on a draft Commission Implementing Decision allowing Member States to extend provisional authorisations granted for the new active substances Acequinocyl, *Adoxophyes orana* granulosus virus strain BV-0001, Aminopyralid, Flubendiamide, Mandipropamid, Metaflumizone, Phosphane, Pyroxsulam and Thiencarbazone.** (Doc. SANCO/11304/2011 Rev. 1) (Legal Base: Article 80(1) of Regulation (EC) No 1107/2009) (Opinion of the Committee via the examination procedure)

*Vote: Unanimous favourable opinion.*

- 2. Exchange of views and possible opinion of the Committee on a draft Commission Implementing Regulation concerning the approval of Tefluthrin as active substance.** (Doc. SANCO/11081/2011 Rev. 3) (draft review report SANCO/12661/2010 Rev. 4) (Legal Base: Article 13(2) of Regulation (EC) No 1107/2009) (Opinion of the Committee via the examination procedure)

The Committee took note of the review report outlined in document SANCO/12661/2010 Rev. 4.

*Vote: Qualified majority by 289 in favour, 17 votes against, 39 votes abstained.*

- 3. Exchange of views and possible opinion of the Committee on a draft Commission Implementing Regulation concerning the approval of Oxyfluorfen as active substance.** (Doc. SANCO/11063/2011 Rev. 7) (draft review report SANCO/11136/2011 Rev. 3) (Legal Base: Article 13(2) of Regulation (EC) No 1107/2009) (Opinion of the Committee via the examination procedure)

The Committee took note of the review report outlined in document SANCO/11136/2011 Rev. 3.

*Vote: Qualified majority by 292 in favour, 14 votes against, 39 votes abstained.*

- 4. Exchange of views and possible opinion of the Committee on a draft Commission Implementing Regulation concerning the approval of Imazalil as active substance.** (Doc. SANCO/11020/2011 Rev. 4) (draft review report SANCO/11021/2011) (Legal Base: Article 13(2) of Regulation (EC) No 1107/2009) (Opinion of the Committee via the examination procedure)

The Committee took note of the review report outlined in document SANCO/11021/2011.

*Vote: Unanimous favourable opinion.*

- 5. Exchange of views and possible opinion of the Committee on a draft Commission Implementing Regulation concerning the approval of Azoxystrobin as active substance.** (Doc. SANCO/11026/2011 Rev. 4) (draft review report SANCO/11027/2011) (Legal Base: Article 13(2) of Regulation (EC) No 1107/2009) (Opinion of the Committee via the examination procedure)

The Committee took note of the review report outlined in document SANCO/11027/2011.

*Vote: Qualified majority by 338 in favour, 7 votes against.*

- 6. Exchange of views and possible opinion of the Committee on a draft Commission Implementing Regulation concerning the approval of Azimsulfuron as active substance.** (Doc. SANCO/11024/2011 Rev. 5) (draft review report SANCO/11025/2011) (Legal Base: Article 13(2) of Regulation (EC) No 1107/2009) (Opinion of the Committee via the examination procedure)

The Committee took note of the review report outlined in document SANCO/11025/2011.

*Vote: Unanimous favourable opinion.*

- 7. Exchange of views and possible opinion of the Committee on a draft Commission Implementing Regulation concerning the approval of Prohexadione as active substance.** (Doc. SANCO/11022/2011 Rev. 3) (draft review report SANCO/11023/2011 Rev. 2) (Legal Base: Article 13(2) of Regulation (EC) No 1107/2009) (Opinion of the Committee via the examination procedure)

The Committee took note of the review report outlined in document SANCO/11023/2011.

*Vote: Unanimous favourable opinion.*

- 8. Exchange of views and possible opinion of the Committee on a draft Commission Implementing Regulation concerning the approval of Profoxydim as active substance.** (Doc. SANCO/11059/2011 Rev. 2) (draft review report SANCO/11198/2011) (Legal Base: Article 13(2) of Regulation (EC) No 1107/2009) (Opinion of the Committee via the examination procedure)

The Committee took note of the review report outlined in document SANCO/11198/2011.

*Vote: Qualified majority by 331 in favour, 7 votes against, 7 votes abstained.*

- 9. Exchange of views and possible opinion of the Committee on a draft Commission Implementing Regulation concerning the approval of Bispyribac as active substance.** (Doc. SANCO/11060/2011 Rev. 2) (draft review report SANCO/11199/2011) (Legal Base: Article 13(2) of Regulation (EC) No 1107/2009) (Opinion of the Committee via the examination procedure)

The Committee took note of the review report outlined in document SANCO/11199/2011.

*Vote: Qualified majority by 331 in favour, 7 votes against, 7 votes abstained.*

- 10. Exchange of views and possible opinion of the Committee on a draft Commission Implementing Regulation concerning the approval of Fluroxypyr as active substance.** (Doc. SANCO/11018/2011 Rev. 3) (draft review report SANCO/11019/2011) (Legal Base: Article 13(2) of Regulation (EC) No 1107/2009) (Opinion of the Committee via the examination procedure)

The Committee took note of the review report outlined in document SANCO/11019/2011.

*Vote: Qualified majority by 338 in favour, 7 votes abstained.*

- 11. Exchange of views and possible opinion of the Committee on a draft Commission Implementing Regulation concerning the approval of Spiroxamine as active substance.** (Doc. SANCO/10888/2011 Rev. 3) (draft review report SANCO/10889/2011) (Legal Base: Article 13(2) of Regulation (EC) No 1107/2009) (Opinion of the Committee via the examination procedure)

The Committee took note of the review report outlined in document SANCO/10889/2011.

*Vote: Unanimous favourable opinion.*

- 12. Exchange of views and possible opinion of the Committee on a draft Commission Implementing Regulation concerning the approval of Kresoxim-methyl as active substance.** (Doc. SANCO/11028/2011 Rev. 4) (draft review report SANCO/11029/2011 Rev. 2) (Legal Base: Article 13(2) of Regulation (EC) No 1107/2009) (Opinion of the Committee via the examination procedure)

The Committee took note of the review report outlined in document SANCO/11029/2011 Rev. 2.

*Vote: Unanimous favourable opinion.*

- 13. Exchange of views and possible opinion of the Committee on a draft Commission Implementing Regulation concerning the approval of 1-Naphthylacetamide as active substance.** (Doc. SANCO/11272/2011 Rev. 1) (draft review report SANCO/11271/2011 Rev. 3) (Legal Base: Article 13(2) of Regulation (EC) No 1107/2009) (Opinion of the Committee via the examination procedure)

The Committee took note of the review report outlined in document SANCO/11271/2011 Rev. 3.

*Vote: Qualified majority by 323 in favour, 22 votes abstained.*

- 14. Exchange of views and possible opinion of the Committee on a draft Commission Implementing Regulation concerning the approval of 1-Naphthylacetic acid (notified as Naphthylacetic acid) as active substance.** (Doc. SANCO/11270/2011 Rev. 1) (draft review report SANCO/11269/2011 Rev. 3) (Legal Base: Article 13(2) of Regulation (EC) No 1107/2009) (Opinion of the Committee via the examination procedure)

The Committee took note of the review report outlined in document SANCO/11269/2011 Rev. 3.

*Vote: Unanimous favourable opinion.*

- 15. Exchange of views and possible opinion of the Committee on a draft Commission Implementing Regulation concerning the approval of Fluquinconazole as active substance.** (Doc. SANCO/11274/2011 Rev. 2) (draft review report SANCO/11273/2011 Rev. 4) (Legal Base: Article 13(2) of Regulation (EC) No 1107/2009) (Opinion of the Committee via the examination procedure)

The Committee took note of the review report outlined in document SANCO/11273/2011 Rev. 4.

*Vote: Qualified majority by 292 in favour, 14 votes against, 39 votes abstained.*

- 16. Exchange of views and possible opinion of the Committee on a draft Commission Implementing Regulation concerning the approval of Acrinathrin as active substance.** (Doc. SANCO/11358/2011 Rev. 2) (draft review report SANCO/11357/2011) (Legal Base: Article 13(2) of Regulation (EC) No 1107/2009) (Opinion of the Committee via the examination procedure)

*Vote postponed.*

- 17. Exchange of views and possible opinion of the Committee on a draft Commission Implementing Regulation concerning the approval of Fluazifop-P as active substance.** (Doc. SANCO/11341/2011 Rev. 2) (draft review report SANCO/11238/2011 Rev. 3) (Legal Base: Article 13(2) of Regulation (EC) No 1107/2009) (Opinion of the Committee via the examination procedure)

*The Committee took note of the review report outlined in document SANCO/11238/2011 Rev. 3.*

France made the following declaration: "Les autorités compétentes françaises précisent que la substance active fluazifop-P est d'importance majeure pour les usages mineurs. Les autorités compétentes françaises demandent que, si des démarches sont entreprises pour lever les restrictions de l'inscription de cette substance, elles soient traitées sans retard et le plus rapidement possible."

*Vote: Qualified majority by 314 in favour, 31 votes against.*

- 18. Exchange of views and possible opinion of the Committee on a draft Commission Implementing Regulation concerning the approval of Terbutylazine as active substance.** (Doc. SANCO/11295/2011 Rev. 2) (draft review report SANCO/11337/2011 Rev. 1) (Legal Base: Article 13(2) of Regulation (EC) No 1107/2009) (Opinion of the Committee via the examination procedure)

The Committee took note of the review report outlined in document SANCO/11337/2011 Rev. 1.

*Vote: Qualified majority by 265 in favour, 63 votes against, 17 votes abstained.*

- 19. Exchange of views and possible opinion of the Committee on a draft Commission Implementing Regulation concerning the approval of Triazoxide as active substance.** (Doc. SANCO/11360/2011 Rev. 2) (draft review report SANCO/11359/2011 Rev. 1) (Legal Base: Article 13(2) of Regulation (EC) No 1107/2009) (Opinion of the Committee via the examination procedure)

The Committee took note of the review report outlined in document SANCO/11359/2011 Rev. 1.

*Vote: Qualified majority by 326 in favour, 19 votes against.*

- 20. Exchange of views and possible opinion of the Committee on a draft Commission Implementing Regulation concerning the approval of Bitertanol as active substance.** (Doc. SANCO/13524/2011 Rev. 7) (draft review report SANCO/13523/2011 Rev. 5) (Legal Base: Article 13(2) of Regulation (EC) No 1107/2009) (Opinion of the Committee via the examination procedure)

*Vote postponed.*